Amid the hype surrounding these glucagon-like peptide-1 (GLP-1) receptors’ efficacy for weight loss, the government has documented around 400 reports of adverse drug reactions (ADRs) potentially linked to the medication that is now being clinically evaluated, officials said.
​Amid the hype surrounding these glucagon-like peptide-1 (GLP-1) receptors’ efficacy for weight loss, the government has documented around 400 reports of adverse drug reactions (ADRs) potentially linked to the medication that is now being clinically evaluated, officials said. by Soban News (international And National News)
